admin

The agency is moving to individual risk assessments to expand blood donor eligibility. The FDA plans to relax rules that for decades have barred gay and bisexual men from donating blood due to concerns about HIV transmission. The draft guidelines open in a new tab […]

Advisors also weigh in on agency's push for annual COVID boosters similar to the flu vaccine By Ingrid Hein FDA vaccine advisors unanimously endorsed the agency's proposal to harmonize primary and booster COVID-19 vaccines to contain a composition

A surveillance system detects a possible link in older people, but many others show none. By Ian Ingram. An early sign of stroke risk was detected in older adults who received the Pfizer-BioNTech bivalent COVID-19 vaccine, the FDA announced in a joint statement late Friday. However, the

Christine Lehmann, MA. Doctors don't seem to be recovering from the early days of the pandemic: their happiness at work and outside of it remains significantly lower than before the pandemic. Doctors also reported similar levels of unhappiness last year. Nearly half of the doctors said they were somewhat or very unhappy.

A group of researchers is evaluating the potential of the first long-acting HIV treatment as a tool for controlling new HIV infections in high-risk groups. Ángel Luis Jiménez. Over the last few years, significant progress has been made in the fight against HIV. From the point of view

Sunlenca twice a year works well for initial HIV treatment. The new injectable antiretroviral keeps HIV under control, but still needs a similarly long-acting partner. • By Liz Highleyman. Sunlenca (lenacapavir), a recently approved long-acting injectable drug for people with multidrug-resistant HIV who have already received treatment, also works well.

By Clarinha Glock. Same-day initiation of pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection is feasible in Latin America, with few early losses during follow-up, high adherence, and long-term commitment. However, issues related to the social and structural determinants of

Researchers halt Mosaic trial after experimental HIV vaccine found to be safe but ineffective. By Liz Highleyman. Another large trial has been paused after Johnson & Johnson's experimental HIV vaccine, which uses the same technology as the company's COVID-19 vaccine,

By Paul Sax We turn to discuss one of the controversial articles published in late 2022 on COVID-19, namely the PANORAMIC study of molnupiravir versus usual care in outpatients with the disease. This is controversial not because the study was poorly conducted or unimportant, but because molnupiravir has been, since

By Liz Highleyman 1980s: The First Antiretroviral The first medical report on AIDS was published in June 1981, and researchers discovered that HIV was the cause of AIDS in 1983. It would be four more years before the Food and Drug Administration (FDA) approved the first antiretroviral drug, the